Avacta Group widens half-year losses as sales slow
Animal and human healthcare company Avacta Group widened its half-year losses as revenues slowed during the introduction of new Optim analytical devices.
Animal and human healthcare company Avacta Group widened its half-year losses as revenues slowed during the introduction of new Optim analytical devices.
The provider of analytical and diagnostic technologies to the pharmaceutical and animal healthcare sectors, posted an operating loss of £0.97m in the six months to the end of January, up from £0.52m the previous year.
Revenues dropped to £1.15m from £1.72m during the transition from Optim1 to Optim2, an analytical instrument designed to probe multiple protein stability-indicating parameters.
MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE

Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
The company has received orders for 10 units since launching the product on February 1st.
During the period, the company invested in training its sales team at ForteBio, the the newly acquired subsidiary of partner Pall Corporation. ForteBio is the key distributor for the US market of the Optim product.
"Revenues fell because Optim sales slowed as we introduced Optim2 and trained up the sales team at ForteBiom," Chief Executive Officer Alastair Smith told Digital Look and Sharecast.
He said it was a transformational period for the company which resulted in a short-term slowdown that will drive performance in the long run.
The company expects to launch its new Affimer reagents next year as development remains in line with management's expectations.
"The antibody replacement technology presents a lot of growth opportunities," he said.
"Over the next half we anticipate further progress across all divisions."
RD
Get the latest financial news, insights and expert analysis from our award-winning MoneyWeek team, to help you understand what really matters when it comes to your finances.
MoneyWeek is written by a team of experienced and award-winning journalists, plus expert columnists. As well as daily digital news and features, MoneyWeek also publishes a weekly magazine, covering investing and personal finance. From share tips, pensions, gold to practical investment tips - we provide a round-up to help you make money and keep it.
-
Michelin Key Hotels 2025: the top destinations in the world
The Michelin Keys have been awarded to spectacular hotels across the world. From Marlon Brando's private resort in Polynesia to a Bvlgari hotel in Tokyo, we look at some of the most extraordinary stays in 2025
-
MoneyWeek news quiz: How much could you get in car finance compensation?
The car finance scandal, inheritance tax, and house prices all made headlines over the past few days. Test your knowledge while reviewing this week’s top stories with MoneyWeek’s news quiz